Display options
Cite
Ng CY, Tzeng IS, Liu SH, et al. Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). J Dermatol. 2017;45(3):309-313doi: 10.1111/1346-8138.14079.
Ng, C. Y., Tzeng, I. S., Liu, S. H., Chang, Y. C., & Huang, Y. H. (2018). Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). The Journal of dermatology, 45(3), 309-313. https://doi.org/10.1111/1346-8138.14079
Ng, Chau Yee, et al. "Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab)." The Journal of dermatology vol. 45,3 (2018): 309-313. doi: https://doi.org/10.1111/1346-8138.14079
Ng CY, Tzeng IS, Liu SH, Chang YC, Huang YH. Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). J Dermatol. 2018 Mar;45(3):309-313. doi: 10.1111/1346-8138.14079. Epub 2017 Oct 05. PMID: 28980716.
Copy Download .nbib Format: NLM
Share it on

J Dermatol. 2018 Mar;45(3):309-313. doi: 10.1111/1346-8138.14079. Epub 2017 Oct 05.

Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).

The Journal of dermatology

Chau Yee Ng, I-Shiang Tzeng, Su-Hsun Liu, Ya-Ching Chang, Yu-Huei Huang

Affiliations

  1. Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
  2. School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  3. Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.
  4. Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan.
  5. Department of Family Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

PMID: 28980716 DOI: 10.1111/1346-8138.14079

Abstract

The associations between psoriasis, metabolic syndrome and cardiovascular events are increasingly recognized. Studies have shown decreased cardiovascular events with the treatment of methotrexate and anti-tumor necrosis factor, however, effects of interleukin (IL)-12/23 blockade remain debatable. Our study investigated the effect of IL-12/23 blockade on the metabolic parameters in patients with psoriasis. We performed a retrospective cohort study to assess 93 consecutive patients with moderate to severe plaque type psoriasis who received IL-12/23 blockade (ustekinumab) for 24 weeks between January 2012 and May 2016. Metabolic parameters and disease activity (Psoriasis Area and Severity Index [PASI] score) at baseline and 24 weeks of treatment were collected. At week 24, the disease activity improved significantly (P < 0.0001), with a significant reduction of erythrocyte sedimentation rate. Conversely, body mass index was significantly elevated in PASI-75 responders at week 24 of treatment and was independent of disease severity. Fasting sugar and triglyceride levels were also elevated at week 24 in both PASI-75 responders and PASI-75 non-responders. Cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) remained unchanged. These metabolic parameters were not correlated with the improvement in disease severity after ustekinumab treatment. Nonetheless, the atherogenic index, LDL/HDL ratio and cholesterol/HDL ratio remained unchanged. Male sex and cigarette smoking are predictors of elevated plasma triglyceride levels. Our results suggest that despite tremendous improvement in disease activity after ustekinumab treatment, obesity, fasting sugar and hypertriglyceridemia still present in these patients. Regular screening of lipid profile, obesity control and smoking cessation are advised during the treatment of ustekinumab especially in male psoriatic patients with predisposing cardiovascular risks.

© 2017 Japanese Dermatological Association.

Keywords: lipid; metabolic; psoriasis; triglyceride; ustekinumab

Publication Types